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Abstract
Background: Dengue virus is transmitted by mosquitoes and has four serotypes. Cross-protection to other serotypes lasting
for a few months is observed following infection with one serotype. There is evidence that low-affinity T and/or B cells from
primary infections contribute to the severe syndromes often associated with secondary dengue infections. such
pronounced immune-mediated enhancement suggests a dengue-specific pattern of immune cell activation. This study
investigates the acute and early convalescent B cell response leading to the generation of cross-reactive and neutralizing
antibodies following dengue infection.
Methodology/Principal Findings: We assayed blood samples taken from dengue patients with primary or secondary
infection during acute disease and convalescence and compared them to samples from patients presenting with non-
dengue related fever. Dengue induced massive early plasmablast formation, which correlated with the appearance of
polyclonal, cross-reactive IgG for both primary and secondary infection. Surprisingly, the contribution of IgG to the
neutralizing titer 4–7 days after fever onset was more than 50% even after primary infection.
Conclusions/Significance: Poly-reactive and virus serotype cross-reactive IgG are an important component of the innate
response in humans during both primary and secondary dengue infection, and ‘‘innate specificities’’ seem to constitute part
of the adaptive response in dengue. While of potential importance for protection during secondary infection, cross-reactive
B cells will also compete with highly neutralizing B cells and possibly interfere with their development.
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Introduction
Symptomatic dengue infection is characterized by pyrexia,
arthralgia, myalgia, headache, rash, vascular leakage and
occasionally hemorrhage. With supportive medical care dengue
fever (DF) normally resolves within two weeks, however in some
cases patients develop dengue hemorrhagic fever (DHF) or the
potentially fatal dengue shock syndrome (DSS). Fever lasts for two
to seven days and coincides with the peak of viremia, although
virus may still be detected in the blood for up to ten days after
fever onset. Common clinical findings are an increased hematocrit
and decreased platelet numbers [1]. Severe disease is more
common in secondary infections, implicating that immune
mechanisms are involved. Efforts to understand the immune basis
of severe dengue have correlated T cell activation, in particular
activation of cells from previous infection, with disease severity [2].
In addition, cross-reactive antibodies from a previous infection
have been suggested to predispose to more severe secondary
disease due to antibody-enhanced infection of dengue target cells
[3,4]. Overall it remains unclear to what extent pre-existing
antibodies or T cells can be correlated with protection or
exacerbation of disease. Antibody-dependent enhanced infections
are potentially caused by non-neutralizing serotype cross-reactive
antibodies.
Cross-reactive, low affinity antibodies are often generated when
B cells are activated polyclonally, such as after infection with
influenza [5], hepatitis C [6], HIV [7] and malaria [8]. Given this
context, we hypothesized that the mechanism of B cell activation is
critical in determining the outcome of dengue infection. Upon
activation, B cells differentiate into plasmablasts that appear in the
circulation between 6 and 8 days after infection. After secondary
infection these plasmablasts produce almost exclusively IgG
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antibodies [9,10], but little is known about the role of plasmablasts
in primary infections due to difficulties in detecting the low
numbers of antigen-specific plasmablasts and logistical constraints
in obtaining early patient material.
It is well established from experiments with human volunteers
that infection with one dengue serotype confers protection to all
four serotypes for a limited period of a few months, after which
protection becomes serotype-specific [11]. The pool of antibodies
produced during acute dengue infection thus seems to be
protective due to the diversity and large quantity of antibodies.
In this study, we investigated which components of the human B
cell response comprised serotype cross-protection. We analyzed
samples from a cohort of patients experiencing acute fever due to
primary or secondary dengue infection or due to an unrelated
cause. Using fresh whole blood samples we found a significant B
cell activation capacity of dengue virus. A transient appearance of
plasmablasts and plasma cells was observed by flow cytometry and
was most pronounced during secondary infection, which could be
explained by the re-activation of cross-reactive memory B cells.
However even after primary infection virus-specific IgG appeared
early, and IgM antibodies contributed less than IgG to virus
neutralization. We hypothesize that poly-reactive B cells of the
IgG isotype are specifically triggered by dengue virus and account
for short-term cross-protection.
Results
Strong B cell activation and plasmablast formation after
dengue infection
To assess the extent and duration of B cell activation and the
consequent differentiation into antibody-secreting cells during
dengue infection, blood samples for analysis were taken from fever
patients at the time of presentation at the clinic, at defervescence
and 15–25 days after onset of fever (Table 1). Patients were
retrospectively grouped as dengue- RT-PCR positive or negative,
with the latter referred to as ‘‘control patients’’ for the rest of this
study. Dengue patients were further grouped into primary or
secondary cases based on the presence of dengue-specific IgG at
the time point of fever (see methods). Four to seven days after onset
of fever, secondary dengue patients possessed a significantly higher
percentage of CD19+,CD202,CD27+,CD1382 plasmablasts [12]
(p = 0.0007) compared to control patients (Fig. 1A). Furthermore,
significantly higher percentages of CD19+,CD202,CD27+CD138+
plasma cells (p = 0.0036) were observed in dengue compared to
control patients between days 4 and 7 after fever (Fig. 1B). The
frequency of plasmablasts and plasma cells during primary
infection appeared higher in dengue- compared to control
patients. Figure 1C shows the gating strategy for plasmablasts
and –cells (grey boxes), representative for one patient followed
over three time points.
Since lymphocyte numbers are lower in dengue patients
compared to control patients [13] absolute numbers of the
different cell types were calculated (Table 2). Plasmablast numbers
were significantly higher in dengue - compared to control patients
(p = 0.033), whereas plasma cells numbers were not significantly
different (p = 0.058). Interestingly, absolute numbers of plasma-
blasts peaked at day 4–7 in dengue patients, in contrast to day 15–
25 in control patients (Table 2).
Taken together, high plasmablast and plasma cell formation was
observed in dengue patients and suggests production of large
amounts of antibodies. Furthermore, higher numbers in secondary
compared to primary dengue cases suggest re-activation of
memory B cells.
Early secretion of dengue cross-reactive IgG antibodies
We next assessed the specificity of the activated B cell response
to dengue. Plasma samples from dengue and control patients were
tested for dengue serotype reactivity on ELISA plates coated with
DENV1, 2, 3 or 4 (Fig. 2). Plasma was diluted 1:200 to 1:25’000
and each sample was measured in duplicate and compared to a
standard sample that was included on each plate for inter-plate
comparison. The ratio of sample/standard for only one dilution is
shown for clarity in Fig. 2. DENV-specific IgM and IgG titers
increased markedly between fever (1–3 days) and early convales-
cence (15–25 days) (Fig. 2A and B). In many secondary cases, a
peak in IgG titer was observed 4–7 days after onset of fever, with
cross-reactivity against all four dengue serotypes. IgG antibody
levels for primary cases increased surprisingly early, between 4–
7days after onset of fever (Fig. 2B).
We next thought of dengue-specific factors that could positively
influence plasmablast formation. A role for B cell activating factor
BAFF for B cell activation and –survival has been demonstrated
[14]. We hypothesized that BAFF could be responsible for the
observed plasmablast response in dengue patients since IL-10,
which is highly up-regulated during acute dengue infection [15],
can induce BAFF-expression [16]. We measured BAFF levels in
the plasma of dengue patients and compared them to levels in
patients with confirmed influenza infection amongst our control
group (Fig. 2C). BAFF concentrations were higher during acute
disease compared to convalescence (Fig. 2C), whereas there was no
significant difference in BAFF levels between primary and
secondary patients (not shown). BAFF produced during acute
disease thus possibly contributes to B cell differentiation. However,
this was not specific for dengue infection, and similar levels were
found in patients with flu (Fig. 2C). To further test whether
DENV-infection could directly induce BAFF, monocyte-derived
DCs (moDCs) were infected and secreted BAFF was measured in
cell culture supernatants (Fig. 2D). moDCs were chosen because
DCs together with monocytes/macrophages are a major source of
BAFF amongst hematopoietic cells [17], and because DCs are
targets cells for DENV infection in humans [18,19]. However,
BAFF-expression in DENV-infected cells was suppressed com-
pared to cells treated with HI-DENV or polyI:C, suggesting that
DCs are unlikely to be a source of BAFF after DENV infection.
Table 1. Patient cohort.
Totala Age (years) Sex Fever at presentation (degC) HCT %c Plt (6103/ul)c
Dengue 31 39.3615.4 14 M, 17F 38.3260.92 41.8469.65 138671
Control group 51b 37.2616.4 27 M, 24F 38.1460.86 47.13610.23 198682
a)not all experiments were done with all patient samples. The numbers of patients for each figure are indicated in the figure legend.
b)nine patients had a confirmed influenza infection and were analyzed as a separate group for Figure 1.
c)time point: 4–7days after onset of fever.
doi:10.1371/journal.pone.0029430.t001
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Figure 1. Polyclonal B cell activation after dengue infection. Fresh blood samples of dengue and control fever patients were analyzed by flow
cytometry at 1–3, 4–7 and 15–25 days after onset of fever. A) CD19+CD202CD27+CD1382 plasmablasts and CD27+CD138+ plasma cells (B) as % of
lymphocytes. squares: other febrile illness (OFI), triangles: primary or secondary dengue infection. Each symbol represents one patient, lines indicate
the mean. A Mann-Whitney test was used for statistical analysis. C) Gating strategy for plasmacells and plasmablasts. One secondary dengue patient
with high plasma blast formation is shown. Blood was taken 3, 4 and 20 days after onset of fever.
doi:10.1371/journal.pone.0029430.g001
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Broad-specificity antibodies bind and neutralize dengue
virus
It is generally accepted that neutralizing titers correlate more
with protection than ELISA titers since a neutralization assay
measures the capacity of antibodies to inhibit viral infection,
whereas an ELISA detects all antibodies that bind to the virus. We
first compared ELISA titers of the plasma of three patients with
primary and three patients with secondary DENV2 infection
(Fig. 3A and B). Cross-reactivity for all four dengue serotypes was
observed for both patient groups but was more pronounced for
secondary patients. It is well documented that neutralizing titers
after secondary infection are largely serotype cross-reactive [20].
Neutralization data for patients with primary infection at early
convalescence are rare though and we therefore compared the
ELISA titers of the patients in Fig. 3A with neutralizing titers
(Fig. 3C). A flow-cytometry based approach was used to detect
infected cells and to determine the plasma dilution at which 50%
virus neutralization was achieved (EC50). The neutralizing titers
against DENV2 were highest (Fig. 3C), but EC50 values against
DENV1 and 3 were comparable, showing that cross-reactivity is a
phenomenon of both primary and secondary infection. The faster
and higher cross-reactive response to all four DENV serotypes
during secondary infection suggests activation or re-activation of a
polyspecific pool of B cells, which rapidly produces large quantities
of anti-dengue antibodies, which are superimposed on pre-existing
titers generated by long-lived plasma cells.
The rapid increase of titers in primary dengue patient 1
suggested pre-existing immunity even though no pre-existing
antibodies were detected by our ELISA and by the PanBio
diagnostics kit.
No hypergammaglobulinemia despite polyclonal B cell
activation
Given the cross-reactivity of both ELISA- and neutralizing
antibodies, we tested whether there was an increase in total
antibody concentrations, which is observed after other viral
infections such as HIV known to activate B cells polyclonally
[21]. There was, however, no significant difference for total IgM,
IgG and IgA between dengue patients and controls (Fig. 4A). To
further assess a potential polyclonal activation of B cells, polio-
specific antibodies were measured during acute disease and
convalescence. Dengue patients showed a slight, but significant
(p,0.05) increase in polio-specific antibodies compared to control
patients at 15–25 days after fever, suggesting that DENV can
activate poly-specific B cells that cross-react with polio virus
(Fig. 4B). The kinetics suggested production of IgG antibodies
from newly activated, polio cross-reactive B cells in dengue
patients, rather than re-activation of polio-specific memory B cells
[22].
Natural IgG neutralizes dengue virus
Natural antibodies act as a first line of defense against pathogens
[23,24]. Particularly at early time points after infection we
expected a substantial contribution of IgM to virus neutralization,
given the increase in IgM ELISA titers at day 4–7 after fever
(Fig. 2A). To determine the contribution of IgM to total
neutralizing antibodies we treated plasma samples with 2-
mercaptoethanol (2-ME) at a concentration that reduces disulfide
bonds in IgM-pentamers while leaving antibody monomers,
including IgG, intact. IgM monomers are not functional because
of their low binding affinity. We found that chemical reduction of
the IgM-pentamers reduced the 50% neutralizing titers (NT50) by
a maximum of 50% in acute and convalescent samples (Fig. 5A
and table 3). This means that already at day 4–7 after onset of
fever upon primary infection IgG constitutes more than half of the
neutralization. To confirm this finding we depleted IgG in plasma
samples of two primary infection patients (Fig. 5B). IgG-depletion
reduced the NT50 from 7175 to 364 and from 310 to 98,
respectively (table 3). Even though the total IgM-concentration
was also affected by depletion with Protein-G the reduction of IgM
Table 2. Absolute numbers of plasmablasts and plasma cells.
CD19+CD20-CD27+CD138- (cells/ml)
day 1–3 day 4–7 day 15–25
Diagnosis OFI 16 dengue 26 dengue OFI 16 dengue 26 dengue negative 16 dengue 26 dengue
n 45 6 8 25 6 8 18 6 6
Mean 6.903 2.893 9.014 16.33 12.93 91.35 10.23 4.94 7.717
Std. Deviation 11.48 2.355 17.79 21.26 12.16 109.2 11.16 4.252 5.75
P valuea 0.46 0.98 0.17
P valueb 0.41 0.006 0.76
CD27+CD138+ (cells/ml)
day 1–3 day 4–7 day 15–25
Diagnosis OFI 16 dengue 26 dengue OFI 16 dengue 26 dengue negative 16 dengue 26 dengue
n 42 6 8 23 6 8 18 6 6
Mean 4.252 1.498 3.458 6.232 4.877 18.59 5.462 6.343 4.47
Std. Deviation 8.145 2.232 5.827 5.948 4.012 16.14 2.88 5.4 2.571
P valuea 0.035 0.35 0.97
P valueb 0.24 0.061 0.42
a)p value comparing OFI with 1u dengue.
b)p value comparing OFI with 2u dengue (Mann Whitney test). Longitudial samples were analyzed. Not all patients were available for the second and third time points.
doi:10.1371/journal.pone.0029430.t002
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Figure 2. Rapid induction of cross-reactive IgG antibodies after dengue infection. Longitudinal plasma samples of dengue patients were
tested by ELISA for dengue-specific IgM (A) and IgG antibodies (B). A and B) Four plasma dilutions from 1:200 to 1:25’000 were measured to exclude
non-specific binding. For the combined illustration of all samples that were analysed the OD450 of one dilution (1:5000 for IgG and 1:1000 for IgM)
was divided by the OD450 of a standard serum that was included on each plate. Time points: 1 = 1–3 days after fever, 2 = 4–7 days after fever, 3 = 15–
25 days after fever. The same patient samples were analyzed for DENV1–4. Binding intensity correlated for all four serotypes, i.e. high binding to
DENV1 would also apply to DENV2, 3 and 4. Primary versus secondary infection status was confirmed with the commercially available Panbio ELISA kit
(Inverness Medical, Australia). The experiment was repeated for selected samples, confirming the original results. C) Concentrations of BAFF were
measured in the plasma of dengue and flu patients at the indicated time points. D) moDCs were infected with DENV, heat-inactivated (HI) DENV,
polyI:C or medium and BAFF was measured in the supernatant at different time points after infection. Data are presented as % of medium control
and are the means6SEM of two independent experiments, done in triplicates. TSV01:medium compared to polyIC:medium is significantly different
(p.0.05, Two-way ANOVA). The source of BAFF in DENV-infected patients is therefore unlikely to be DCs.
doi:10.1371/journal.pone.0029430.g002
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was smaller than the reduction in NT50, confirming a crucial role
of IgG for early DENV neutralization and showing that the
neutralizing activity cannot be attributed solely to IgM secreted
from newly activated naı¨ve B cells.
Interestingly, dengue-specific IgG ELISA titers correlated with
plasma cell frequencies at day 4–7 for primary and secondary
cases, whereas dengue-specific IgM ELISA titers did not (Fig. 5C).
This finding indicated that early dengue-binding and -neutralizing
IgG antibodies are produced by newly activated B cells that
circulate as plasma cells, whereas IgM-producing cells might not
appear as plasma cells in the blood.
Serotype cross-reactivity is maintained in the memory B
cell pool
The early appearance of dengue serotype cross-reactive IgG
antibodies in the plasma of secondary infection patients (Fig. 2B)
could be either newly activated polyclonal IgG or re-activated
cross-reactive memory B cells. To address this question we studied
the specificity of memory B cells. We assessed the specificity for
structural (E-protein) and for non-structural (NS1) protein by
ELISPOT. Frozen PBMCs from secondary dengue patients and
healthy donors with previous dengue infection were polyclonally
stimulated according to the method developed by S. Crotty et al.
[25], before overnight incubation on DENV-protein coated
ELISPOT plates. Dengue-specific and total IgG antibody-
secreting cells (ASCs) were analyzed (Fig. 6A). The number of
IgG spots amongst unstimulated cells (if present) was deducted
from the total numbers of IgG producing ASCs in all experiments
shown in Fig. 6B–D. In this way we excluded plasma cells (if any)
and analyzed only memory B cells.
For secondary patients we could detect E-specific memory B cell
frequencies of up to 2% of total IgG memory cells during early
convalescence (day 15–25 after fever), whereas specific memory
could only be detected in one out of four primary patients during
early convalescence (Fig. 6B). We next assessed memory B cells in
healthy donors with a history of dengue infection based on anti-
dengue IgG ELISA. While protection against re-infection with
dengue is serotype-specific [11], we observed cross-reactivity for E-
specific (Fig. 6C) and NS1-specific memory B cells (Fig. 6D). Even
though the numbers of memory cells were lower in healthy donors
with a history of dengue infection compared to patients at early
convalescence, cross-reactivity was maintained over time. As a
control for non-specific binding, seven patients without previous
dengue infection were tested, and none exhibited B cell reactivity
to whole DENV particles or non-structural protein 1 (NS1) protein
whereas total IgG memory B cells were efficiently activated.
Interestingly, for one DENV-ELISA negative healthy donor we
detected NS1-specific memory cells. Moreover, the primary
patient with detectable DENV3 memory (Fig. 6B, extreme right)
showed no detectable anti-dengue IgG antibodies by ELISA
during the acute disease, yet rapidly increasing IgG titers at day 4–
7 (Fig. 3, patient 1). These two cases show that B cell memory can
still be detected in the absence of circulating antibodies.
Discussion
Antibodies produced early during dengue infection exhibit low
specificity and affinity. Cross-serotype specific protection has been
demonstrated in humans for at least three months after infection
by Sabin et al. during world war II. However, it cannot be
concluded from those experiments whether cross-protection was
mediated exclusively by antibodies and/or by innate immunity
and T cells [11]. Very low incidence of dengue infections in
newborns younger than 6 months in endemic areas argue for the
protective value of maternal antibodies in the absence of specific T
cells [26,27].
The correlation of pre-existing immunity with disease severity is
intriguing. Immune-enhancement has been observed for HIV and
influenza infection [28,29], yet an impact on the clinical outcome
is known particularly for dengue disease. An infection-enhancing
role for non-neutralizing antibodies has been suggested based on
in vitro infection of the K562 cell line or primary monocytes in the
presence of serum or monoclonal antibodies [30,31]. However, the
relevance in humans is still uncertain. Three recent studies have
shed light on the B cell repertoire of human memory B cells. The
common finding is that most memory B cells isolated several
months after infection are dengue serotype cross-reactive [30,32–
34].
Few reports address the specificity of the acute B cell response
during primary and secondary infection in humans [35], and the
aim of this current study was to analyze the time point of B cell
activation, the phenotype of B cells appearing after infection, the
specificity of antibodies secreted during acute disease and,
eventually, establishment of specific B cell memory.
During acute disease at day 4–7 after onset of fever we found
high numbers of plasmablasts, which coincided with the
appearance of dengue-specific IgG antibodies (Fig. 1 and 2).
The early IgG titer implies that B cells were already isotype-
switched at the time point of activation. Poly-specific B cells
producing ‘‘natural antibodies’’ act as a first line of defense after a
viral infection and have been first described in mice [24]. In mice,
natural antibodies are thought to be derived mostly from B1 cells
in the peritoneum and gut [36]. In higher vertebrates, natural
antibodies can be of the IgM, IgG and IgA isotype [37].
The massive activation of cross-reactive B cells during acute
secondary disease could result in a competition for T cell help at
the expense of new neutralizing B cells, as has been shown in a
mouse model of infection with lymphocytic choriomeningitis virus
[38]. A concurrent B cell exhaustion could explain lower absolute
plasmablast numbers in dengue patients compared to control
patients at convalescence (table 2). This competition phenomenon
may, at least in part, result in the increased risk associated with
secondary infections, given that less efficient neutralization can be
achieved against the new serotype.
Increased levels of BAFF in patients with viral infections may
support plasmablast and plasmacell differentiation [14]. Hemato-
poietic cells are probably not the source of BAFF during dengue
infection based on three observations: We were unable to detect
Figure 3. Cross-binding and cross-neutralizing IgG. Longitudinal plasma samples of three patients with primary DENV2 infection (A and C) and
three patients with secondary DENV2 infection (B) were analyzed at the following time points after onset of fever: 1–3 days, 4–7 days and 15–25 days.
Plasma samples were diluted three-fold over a range of 1:200 to 1:437’400 and analyzed by ELISA (A and B) and in a neutralization assay (C) for all four
serotypes. A) ELISA with plasma from patients with primary infection with DENV2. B) ELISA with plasma from patients with primary infection with
DENV2. Cross-binding to all four serotypes was observed after primary infection and was more pronounced after secondary infection. C) For the
neutralization assay 1:200 to 1:437’400 diluted plasma samples were incubated with a constant amount of virus and the percentage of infected cells
for each plasma dilution was determined by flow cytometry. EC50 values after curve fit are shown in the upper left of each graph. All curves fit with
an R2.0.95 except for DENV4 of patient 3, where the R2 is 0.78. The results of both assays are representative of at least two separate experiments for
all patients and time points.
doi:10.1371/journal.pone.0029430.g003
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BAFF in the supernatant of DENV-treated whole PBMCs, THP-1
monocytes produced BAFF unspecifically with or without stimuli
(data not shown), and BAFF production in moDCs was even
inhibited by DENV (Fig. 2D). Alternative sources of BAFF such as
fibroblasts or endothelial cells [39–41] may therefore be more
relevant in the context of DENV infection.
Next, we addressed how polyclonal activation was translated
into memory since protection is serotype-specific. Dengue-specific
Figure 4. Broad specificity of dengue-induced antibodies. A)
Total concentration of IgM, IgA and IgG in the plasma of dengue- and
control OFI patients 1–3 days, day 4–7 and day 15–25 after onset of
fever. Means6SD, n = 7–10 for dengue-negative and n= 9–16 for
dengue-positive patients. A student’s t test to compare dengue-
positive with fever control samples was performed. B) Polio virus-
specific antibodies in paired plasma samples from dengue (grey boxes)
and fever control patients (white boxes) 1–3 days of fever, day 4–7 and
day 15–25 after onset of fever. Data are combined from three individual
experiments, n = 18 for dengue, n = 21 for OFI. A Two-Way Repeated
Measures ANOVA test with Bonferroni Post-Hoc test showed a
significant difference between dengue and OFI at day 15–25.
doi:10.1371/journal.pone.0029430.g004
Figure 5. Contribution of IgM and IgG to virus neutralization. A)
Plasma samples of primary patients 2 and 3 (same patients as in Fig. 3)
collected during acute disease and early convalescence were treated with
0.1 M 2-Mercaptoethanol (2-ME) or medium before serial dilution and
incubation with virus. 1:200 to 1:437’400 diluted plasma samples were
incubated with a constant amount of virus and the percentage of
infected cells for each plasma dilution was determined by flow
cytometry. B) Plasma samples from two primary patients were IgG-
depleted and analyzed as in (A). Lower panels show ELISA results to
confirm IgG-depletion. 50% neutralizing titers NT50 are summarized in
table 3. C) IgM and IgG binding to DENV3 (ELISA; ODsample/ODstandard
of plasma samples) were correlated with % plasmacells amongst
lymphocytes at day 4–7 after fever onset (refer to Fig. 1). Each symbol
represents one patient, n = 9 (6 secondary and 3 primary infections). SR:
Spearman R. The correlation with IgG is significant, p = 0.03.
doi:10.1371/journal.pone.0029430.g005
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memory B cells were successfully detected in patients with
secondary infection and in dengue-immune healthy donors.
Approximately 60% of the population in Singapore has antibodies
against DENV indicating previous exposure to the virus. For the
detection of memory B cells by ELISPOT in healthy donors we
chose individuals with detectable DENV-specific IgG (Fig. 6C).
However, memory B cells can exist in the absence of a detectable
DENV-specific IgG titer (Fig. 6D). The frequency of memory B
cells after primary infection was generally below the detection limit
of our assay (1–10 in 106 cells). This implies activation and
expansion of broadly specific B cells during primary infection and
the formation of serotype-cross-reactive memory B cells, which are
re-activated and expanded during secondary infection. A recent
report by Mathew et al., shows that early memory B cells 9–11
days after primary infection are serotype-specific whereas memory
B cells from the same individual analyzed six months after
infection are cross-reactive [35]. While serotype cross-reactivity of
memory B cells after secondary infection shown in this report was
in line with the mentioned study [35] we could not detect dengue-
specific memory B cells 15–25days after primary infection even
though numbers of total IgG-producing memory cells were as high
as for secondary infection patients. The discrepancy between our
study and the one by Mathew et al. might be due to the different
time points analyzed and due to different B cell re-stimulation
protocols. Importantly, Mathew et al did not seem to differentiate
between plasmablasts and re-activated memory B cells whereas we
show memory B cells only (see Material and Methods).
The binding of dengue-patient plasma to polio virus was
increased compared to flu patient plasma (Fig. 4C) and supports
the notion that dengue virus is a polyclonal B cell stimulator. Even
though polio is given as a childhood vaccination in Singapore, we
do not think that dengue infection re-activates polio-specific
memory cells, because this would have resulted in an increase in
polio-specific titer earlier than 15–25 days after fever [22] [42].
Binding to polio virus was not significantly higher in secondary
patients compared to primary patients (not shown). Besides
binding to polio antigen, we also observed increased binding of
dengue patient plasma to LPS by ELISA, but not to double-
stranded or single stranded DNA (data not shown). This finding
suggests that potentially cross-reactive B cells are activated by
dengue while B cell tolerance is maintained [43]. Despite reports
of binding of NS1-specific antibodies to platelets or endothelial
cells [44], we are not aware of any published incidence of
autoimmune disease after dengue infection in humans.
From the data presented we suggest the following sequence of
events: low-affinity, natural B cells are abundantly activated during
primary dengue infection, resulting in a temporary dengue-group-
specific protection for several weeks. In the long term, dengue
serotype cross-reactive B cells are maintained in the memory
pool, possibly alongside serotype-specific long-lived plasma cells.
Memory B cells can be maintained even in the absence of
detectable antibodies. Given the highly efficient re-activation of B
cells as part of a phenomenon called ‘‘original antigenic sin’’ it will
be important to monitor a balanced antibody response against all
four serotypes, which is probably more relevant than absolute
titers for protection.
Materials and Methods
Patients and healthy donors
As part of the prospective Early Dengue (EDEN) infection and
outcome study in Singapore [13], adult patients (age .21 years)
presenting at community primary care polyclinics with acute onset
fever (.38.5uC for less than 72 h) without rhinitis or clinically
obvious alternative diagnoses, were included in the study. A total
of three whole blood samples were collected into EDTA-
vacutainer (Becton Dickinson) tubes at recruitment (acute phase)
and 4–7 days (defervescence) and 3–4 weeks after fever onset
(convalescence) (Table 1). Patients were diagnosed by DENV-
specific RT-PCR. DENV-specific IgM and IgG antibodies were
detected by the ELISA method described here, and confirmed
using the commercially available PanBio kit (Inverness Medical,
Australia). DENV-RT-PCR positive patients with DENV-specific
IgG antibodies at the time point of fever were classified as having
secondary infections. Hematological parameters were measured
using an externally quality controlled hematocytometer (Sysmex
pocH 100i).
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The research involving fever
patients enrolled in the EDEN study was approved by the
Institutional Review Board of Singapore National Healthcare
Group Ethical Domain and patients gave written informed
consent. Blood from anonymous healthy donors was taken with
written donor consent and the use of the samples for this study was
approved by the Health Sciences Authority, Singapore.
Cell lines and virus strains
All viruses used were produced in C6/36 mosquito cells
(ATCC). Following strains were used: DENV1 167 isolated from
a patient in Singapore [13], DENV2 TSV01 [45], DENV3
VN32/96 and My05 34610, and DENV4 My04 31580, which are
isolates from dengue patients and are a gift from Dr. Cameron
Simmons, Oxford University Clinical Research Unit, Viet Nam
and Prof. Shamala Devi, University of Malaya, respectively.
Table 3. 50% neutralizing titer (NT50) of 2-ME-treated (IgM-inactivated) and IgG-depleted plasma.
4–7 days 15–25 days
2-ME-treated 2 + 2 +
Patient 2 439 (R2 0.82)* 200 (R2 0.5) 14’393 (R2 0.98) 8520 (R2 0.97)
Patient 3 610 (R2 0.86) 295 (R2 0.9) 2603 (R2 0.98) 1058 (R2 0.94)
IgG depleted 2 +
Patient 7 7175 (R2 0.98) 364 (R2 0.94)
Patient 8 310 (R2 0.92) 98 (R2 0.99)
*NT50 (R2 of curve fit).
doi:10.1371/journal.pone.0029430.t003
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ELISA
For DENV-specific ELISA, maxisorp plates (Nunc) were coated
with PEG-precipitated DENV serotypes 1–4. Plates were blocked
with PBS, 0.05% Tween 20 (PBST) and 3% skimmed milk. Sera
and a standard containing pooled dengue-IgG positive plasma were
diluted in blocking buffer 1:200, 1:1000, 1:5000 and 1:25000 and
Figure 6. No serotype-specific selection into the memory B cell pool. A) Representative wells of the ELISPOT coated with anti-Ig, whole virus
particles (E-specific B cells) or NS1 protein. Spots were detected with an anti-IgG antibody. B–D) cells were re-stimulated for six days before incubation
on ELISPOT plates for the detection of memory B cells. B) Frequency of E-specific amongst total IgG-ASC in dengue patients 15–25 days after onset of
fever. All patients had a DENV2 infection. Memory cells cross-reacting to two or more dengue serotypes but not necessarily binding to DENV2 were
detected for most secondary patients, whereas the frequency of dengue-specific memory cells was usually below the detection limit for primary
patients. C) Frequency of E-specific ASCs in healthy donors with dengue-specific IgG antibodies. D) Frequency of NS1-specific ASCs in healthy donors
with or without dengue-specific IgG antibodies. B–D) Each data point in the x axes represents one donor, and values are the means of duplicates.
doi:10.1371/journal.pone.0029430.g006
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incubated on the virus-coated plates for one hour at RT before
washing with PBST. Anti-human IgG-HRP (Sigma) was then
added at a concentration of 1:2000 and incubated for one hour at
RT. After washing, 3,3,5,5-tetramethylbenzidine HRP substrate
solution (Sigma) was added. The color reaction was stopped with
1 M HCl. To allow for inter-plate differences in coating and non-
specific background binding, each sample OD is expressed relative
to the OD of the standard. For clarity, the ratio of only one dilution
per sample and time point is shown in Figure 2.
In some cases anti-polio antibodies were quantified as a measure
of the non-dengue immune response. Polio-specific Abs were
detected with an ELISA kit (AlphaScience GmbH, Riedstadt,
Germany), following the company’s instructions. Total amounts of
IgM, IgA and IgG antibodies were detected by coating plates
with anti-IgM, -IgA (Sigma) and -total Ig antibodies (Caltag),
respectively. A standard was included for all isotypes (Sigma).
Bound antibodies were detected using HRP-conjugated antibodies
against IgM, IgA and IgG (Sigma), with TMB as the substrate.
Neutralization assay
A flow cytometry-based neutralization assay described earlier
was used with modifications [46]. BHK21 cell monolayers were
grown in 96well plates. Heat-inactivated plasma samples were
diluted 1:200, 1:2000, 1:20’000 and 1:200’000 in triplicates in
RPMI without FCS and incubated with DENV 1 (167), 2
(TSV01), 3 (VN32/96) or 4 (My04 31580) at approx. MOI 1 for
1 h at 37degC. For some assays, equal amounts of plasma and
0.1 M 2-ME were incubated at 55uC for 1 h to reduce disulfide
bonds in IgM pentamers. For depletion of IgG 150 ul of plasma
were incubated with 200 ul washed Protein-G agarose beads
(Millipore) overnight at 4degC on a rotating wheel. Protein-G
beads were pelleted by centrifugation and the supernatant (IgG-
depleted plasma) was transferred into a new tube. Treated or
untreated plasma samples were dilution with medium and
incubated with DENV. Plasma-virus mixtures were then trans-
ferred onto the BHK21 monolayers and incubated for 2 h at
37degC before adding RPMI, 5% FCS. After an incubation time
of two or three days, cells were stained intracellularly with
antibodies against NS1 and E protein and analyzed using an
LSRII (Becton Dickinson). Data were analyzed using FlowJo
software (TreeStar Inc.). Percentages of infected cells were plotted
against the dilution factor and the EC50 was calculated with
Prism5 (Graphpad Software) applying a three-parameter non-
linear curve fit. Only values with a curve fit of R2.0.9 were
considered.
Monocyte-derived DCs
Monocytes were sorted from healthy donor PBMCs using CD14-
beads (STEMCELL). Purity of CD14+ cells was 85%. Cells were
incubated with human recombinant GM-CSF (50 ng/ml) and IL-4
(10 nl/ml) (both from ImmunoTools) in RPMI, 10% FCS for five
days, adding fresh medium at day 3. Cells were harvested and
analyzed by flow cytometry. 50–70% of cells were CD1a+CD142
whereas the rest of the cells were CD1a2CD142. 46105 cells per
condition were stimulated in triplicates with DENV2 (TSV01)
MOI2, heat-inactivated DENV2, 10 ug/ml polyI:C LMW (Invivo-
Gen) in 0.5 ml RPMI, 10% FCS. 100 ul supernatant was collected
24 h, 48 h and 72 h later for BAFF ELISA, replenishing medium
with 100 ul fresh medium without stimuli.
B cell restimulation and ELISPOT
PBMCs were restimulated with CpG, Pokeweed Mitogen
(PWM) (a kind gift from Dr. Shane Crotty, La Jolla) and Protein
A from Streptococcus Aureus (Sigma) for five to six days according
to the method published by Crotty et al [25]. The results were
similar with fresh and frozen samples. ELISPOT plates (Millipore)
were coated with PEG-precipitated virus, anti-NS1 antibody (kind
gift from Dr. Marie Flamand) or anti-human Ig (Caltag) at 4uC
overnight, and were blocked for two hours at 37uC with RPMI,
1% FCS. For the detection of NS1-specific B cells, NS1 produced
from infected Vero cells [47] was incubated for one hour on anti-
NS1 coated wells before non-specifically bound protein was
washed away. Re-stimulated cells were washed twice before their
addition to the blocked plates. To quantify total IgG antibody-
secreting cells (ASCs), 250–25,000 cells were added to the IgG-
coated wells, whereas 56105 cells were added to each dengue-
coated well. Cells were incubated on the plates overnight at 37uC,
5% CO2. Cells were washed away with PBST the following day
and anti-human IgG-HRP (Sigma) was added at a dilution of
1:1000 and incubated for one hour at RT. Spots representing Ig-
secreting B-cells were visualized with AEC substrate. Plates were
washed and dried before spots were counted using an Immuno-
Spot UV analyzer with BioSpotH Software (Cellular Technology
Ltd). The percentage of dengue-specific memory B cells was
calculated by dividing the number of dengue specific- by the total
number of IgG-secreting cells. If present, spots detected in IgG-
coated control wells, which were incubated with cells cultured in
medium without stimuli were deducted from total IgG-secreting
cells since these cells likely represent plasmablasts/cells and not
memory cells.
Flow Cytometry
Fresh whole blood or frozen PBMCs were labeled with
antibodies recognizing CD20, CD27, CD19 (Biolegend) and
CD138 (BD Pharmingen). For analysis, cells were resuspended in
FACS buffer containing 1% formalin and analyzed using a FACS
Calibur. Data were analyzed using FlowJo software (TreeStar
Inc.).
Statistical Analysis
All statistical analyses were carried out using Prism5 (Graphpad
Software). The statistical test used is indicated in the figure legend.
P values equal to or less than 0.05 considered significant.
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